{"data": [{"paragraphs": [{"qas": [{"id": "64403ab057b1c7a31500004d_001", "question": "How many injections of CLS-TA did the patients participating in the PEACHTREE trial receive?", "answers": []}], "context": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression."}, {"qas": [{"id": "6411b678201352f04a000036_001", "question": "is prosopagnosia inherited or  acquired?", "answers": []}], "context": "Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquired form of prosopagnosia we studied the congenital form"}, {"qas": [{"id": "6411b678201352f04a000036_002", "question": "is prosopagnosia inherited or  acquired?", "answers": []}], "context": "Congenital prosopagnosia (cPA) is a selective impairment in the visual learning and recognition of faces without detectable brain damage or malformation. There is evidence that it can be inherited in an autosomal dominant mode of inheritance."}, {"qas": [{"id": "6411b678201352f04a000036_003", "question": "is prosopagnosia inherited or  acquired?", "answers": []}], "context": "Here we report a follow-up examination on M.T., suffering from acquired prosopagnosia following a large unilateral right-hemispheric lesion in frontal, "}, {"qas": [{"id": "643bc8f957b1c7a31500002b_001", "question": "Where are promoters typically found in DNA?", "answers": []}], "context": "A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5' end of the transcription initiation site. "}, {"qas": [{"id": "643bc8f957b1c7a31500002b_002", "question": "Where are promoters typically found in DNA?", "answers": []}], "context": "Promoters mark the start of every transcript and are an important class of regulatory elements."}, {"qas": [{"id": "64403be357b1c7a31500004e_001", "question": "What was the duration of the follow-up period of patients in the PEACHTREE clinical trial?", "answers": []}], "context": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression."}, {"qas": [{"id": "6440396957b1c7a31500004b_001", "question": "What is the mode of delivery of the drug XIPERE?", "answers": []}], "context": "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. Suprachoroidal (SC) delivery facilitates targeting, compartmentalization, and durability of small molecule suspensions, thereby potentially addressing some of the efficacy, safety, and treatment burden limitations of current retinal therapies. "}, {"qas": [{"id": "6440396957b1c7a31500004b_002", "question": "What is the mode of delivery of the drug XIPERE?", "answers": []}], "context": "Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions."}, {"qas": [{"id": "6431708a57b1c7a315000017_001", "question": "Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?", "answers": []}], "context": "We explored the direct impact of T1AM on cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP) expression. A"}, {"qas": [{"id": "6431708a57b1c7a315000017_002", "question": "Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?", "answers": []}], "context": "In hypertrophic cardiomyocytes, after up-regulating the expression of miR-145, the relative messenger ribonucleic acid (mRNA) and protein expressions of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) induced by PE decreased."}, {"qas": [{"id": "6431708a57b1c7a315000017_003", "question": "Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?", "answers": []}], "context": "Stretching of cultured cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP). Intracellular calcium-elevating agents such as the calcium ionophore A23187,"}, {"qas": [{"id": "640f8641201352f04a00002c_001", "question": "Where in the body would  Schlemm's canal be found", "answers": []}], "context": " This retrospective case series included patients with PCG who underwent trabeculotomy using an illuminated microcatheter with the intent of catheterizing the full circumference of Schlemm's canal in a single procedure"}, {"qas": [{"id": "640f8641201352f04a00002c_002", "question": "Where in the body would  Schlemm's canal be found", "answers": []}], "context": "To study the effect of 3 Schlemm's canal (SC) microinvasive glaucoma surgery (MIGS) devices on outflow facility.DESIGN: Paired comparisons, randomized design, baseline-controlled study.P"}, {"qas": [{"id": "640f8641201352f04a00002c_003", "question": "Where in the body would  Schlemm's canal be found", "answers": []}], "context": "Outflow Facility Effects of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices."}, {"qas": [{"id": "640f8641201352f04a00002c_004", "question": "Where in the body would  Schlemm's canal be found", "answers": []}], "context": "Previously, blood reflux from Schlemm's canal (SC) after long-standing glaucoma surgery was reported in eyes treated with excisional LOT"}, {"qas": [{"id": "640f8641201352f04a00002c_005", "question": "Where in the body would  Schlemm's canal be found", "answers": []}], "context": "AIM: to comparatively evaluate the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscleral removing of the external wall of Schlemm's canal with subsequent laser trabeculopuncture in patients with open-angle glaucoma "}, {"qas": [{"id": "644009c557b1c7a315000041_001", "question": "What is the mode of inheritance of Friedreich\u2019s ataxia?", "answers": []}], "context": "Friedreich's Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (DRG), cerebellar dentate nuclei and heart. "}, {"qas": [{"id": "64371a4257b1c7a315000029_001", "question": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?", "answers": []}], "context": "Coordinated gene expression allows spatiotemporal control of cellular processes and is achieved by the cotranscription/translation of functionally related genes/proteins. Prokaryotes evolved polycistronic messages (operons) to confer expression from a single promoter to efficiently cotranslate proteins functioning on the same pathway."}, {"qas": [{"id": "64371a4257b1c7a315000029_002", "question": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?", "answers": []}], "context": "The arrangement of functionally-related genes in operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression by co-transcription."}, {"qas": [{"id": "64371a4257b1c7a315000029_003", "question": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?", "answers": []}], "context": "Clustering of functionally related genes in operons allows for coregulated gene expression in prokaryotes."}, {"qas": [{"id": "6440377c57b1c7a315000049_001", "question": "What is the active ingredient of Xipere?", "answers": []}], "context": "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. "}, {"qas": [{"id": "6441057657b1c7a315000052_001", "question": "What is the most commonly used pain scale for the measurement of pain in children?", "answers": []}], "context": " Face, leg, activity, cry, and consolability (FLACC) scores for postoperative pain were also assessed."}, {"qas": [{"id": "6441057657b1c7a315000052_002", "question": "What is the most commonly used pain scale for the measurement of pain in children?", "answers": []}], "context": "The FLACC and COMFORT scales were utilized to assess pain"}, {"qas": [{"id": "6441057657b1c7a315000052_003", "question": "What is the most commonly used pain scale for the measurement of pain in children?", "answers": []}], "context": "Postoperative pain was assessed using the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC) scale. "}, {"qas": [{"id": "6441057657b1c7a315000052_004", "question": "What is the most commonly used pain scale for the measurement of pain in children?", "answers": []}], "context": "The pain experience (intense, moderate, or mild) was evaluated by the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r)."}, {"qas": [{"id": "6441057657b1c7a315000052_005", "question": "What is the most commonly used pain scale for the measurement of pain in children?", "answers": []}], "context": " Daily assessment and documentation for pain (81%) and sedation (87%) was reported by most of the PICUs, using the preferred validated FLACC scale (54%) and the COMFORT Behavioural scale (48%), respectively."}, {"qas": [{"id": "64257c9c690f196b5100004b_001", "question": "What is DILI-CAT used for?", "answers": []}], "context": "We utilised a novel DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development."}, {"qas": [{"id": "64257c9c690f196b5100004b_002", "question": "What is DILI-CAT used for?", "answers": []}], "context": "A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development."}, {"qas": [{"id": "64257c9c690f196b5100004b_003", "question": "What is DILI-CAT used for?", "answers": []}], "context": "DILI-CAT, a clinically intuitive, data-driven, computer-assisted scoring algorithm, is a useful tool for early detection of drug's hepatotoxicity in clinical drug development."}, {"qas": [{"id": "6429e85e57b1c7a315000009_001", "question": "What process involves metabolite-sensing mRNAs to control gene expression?", "answers": []}], "context": "These results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches might be representatives of an ancient form of genetic control."}, {"qas": [{"id": "6429e85e57b1c7a315000009_002", "question": "What process involves metabolite-sensing mRNAs to control gene expression?", "answers": []}], "context": "Genetic control by metabolite-binding mRNAs is widespread in prokaryotes. These riboswitches are typically located in noncoding regions of mRNA, where they selectively bind their target compound and subsequently modulate gene expression. We have identified mRNA elements in fungi and in plants that match the consensus sequence and structure of thiamine pyrophosphate-binding domains of prokaryotes."}, {"qas": [{"id": "6429e85e57b1c7a315000009_003", "question": "What process involves metabolite-sensing mRNAs to control gene expression?", "answers": []}], "context": "Metabolite-sensing mRNAs, or \"riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism. Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions, harboring expression-controlling elements."}, {"qas": [{"id": "6429e85e57b1c7a315000009_004", "question": "What process involves metabolite-sensing mRNAs to control gene expression?", "answers": []}], "context": "Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs) that can adopt different conformations to regulate gene expression. The binding of specific small molecule or ion ligands, or other RNAs, influences the conformation the riboswitch adopts."}, {"qas": [{"id": "6440393157b1c7a31500004a_001", "question": "Which year was XIPERE approved by the FDA?", "answers": []}], "context": "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae), administered via a microneedle-based device, the SCS Microinjector\u00ae. "}, {"qas": [{"id": "6415b3b4690f196b51000009_001", "question": "What color light does the the inhibitory receptor halorhodopsin (eNpHR) respond to?", "answers": []}], "context": "Here we report that targeting the codon-optimized form of the light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis (hereafter abbreviated Halo) to genetically-specified neurons enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light."}, {"qas": [{"id": "6429fad757b1c7a31500000e_001", "question": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?", "answers": []}], "context": "A critical regulatory element in many promoters transcribed by RNA polymerase II is the \"TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation site."}, {"qas": [{"id": "6429fad757b1c7a31500000e_002", "question": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?", "answers": []}], "context": "About 24% of human genes have a TATA-like element and their promoters are generally AT-rich; however, only approximately 10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR)."}, {"qas": [{"id": "6429fad757b1c7a31500000e_003", "question": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?", "answers": []}], "context": "TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin."}, {"qas": [{"id": "6429fad757b1c7a31500000e_004", "question": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?", "answers": []}], "context": "The TATA-binding protein (TBP) is one of the major components of the human TFIID multiprotein complex. It is important in directing the initiation of RNA transcription at a site immediately downstream of the TATA sequence (TATA box) found in many eukaryotic promoters. "}, {"qas": [{"id": "64402e7757b1c7a315000044_001", "question": "How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.", "answers": []}], "context": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort)"}, {"qas": [{"id": "64402e7757b1c7a315000044_002", "question": "How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.", "answers": []}], "context": "Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements."}, {"qas": [{"id": "64425ce357b1c7a315000059_001", "question": "What is the incidence of Facioscapulohumeral Muscular Dystrophy?", "answers": []}], "context": "Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence."}, {"qas": [{"id": "64425ce357b1c7a315000059_002", "question": "What is the incidence of Facioscapulohumeral Muscular Dystrophy?", "answers": []}], "context": "It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000. Overall lifespan is not affected significantly."}, {"qas": [{"id": "63f581e933942b094c000007_001", "question": "Risdiplam is used for treatment of which disease?", "answers": []}], "context": "Risdiplam (Evrysdi)-an orally bioavailable, small molecule approved by the US Food and Drug Administration and more recently by the European Medicines Agency for the treatment of patients \u22652 months of age with spinal muscular atrophy-is presented here as a case study."}, {"qas": [{"id": "63f581e933942b094c000007_002", "question": "Risdiplam is used for treatment of which disease?", "answers": []}], "context": "An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy."}, {"qas": [{"id": "63f581e933942b094c000007_003", "question": "Risdiplam is used for treatment of which disease?", "answers": []}], "context": "OBJECTIVE: The US risdiplam expanded access program (EAP; NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy (SMA) who had no satisfactory treatment options access to risdiplam prior to commercial availability. "}, {"qas": [{"id": "63f581e933942b094c000007_004", "question": "Risdiplam is used for treatment of which disease?", "answers": []}], "context": "SMN1 produces SMN, a ubiquitously expressed protein, that is essential for the development and survival of motor neurons. Major advances and developments in SMA therapeutics are shifting the natural history of the disease. With three relatively new available therapies, nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi), patients survive longer and have improved outcomes. "}, {"qas": [{"id": "6431f7de57b1c7a31500001b_001", "question": "What gene is mutated in Friedreich's ataxia?", "answers": []}], "context": "Friedreich's ataxia (FRDA) is an autosomal recessive disease caused by an intronic guanine-adenine-adenine (GAA) triplet expansion in the frataxin (FXN) gene, which leads to reduced expression of full-length frataxin (1-210) also known as isoform 1. "}, {"qas": [{"id": "6431f7de57b1c7a31500001b_002", "question": "What gene is mutated in Friedreich's ataxia?", "answers": []}], "context": "Friedreich's ataxia (FRDA) is an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of frataxin (FXN) gene. "}, {"qas": [{"id": "6431f7de57b1c7a31500001b_003", "question": "What gene is mutated in Friedreich's ataxia?", "answers": []}], "context": "Friedreich ataxia, the most common hereditary ataxia, is a neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin."}, {"qas": [{"id": "6431f7de57b1c7a31500001b_004", "question": "What gene is mutated in Friedreich's ataxia?", "answers": []}], "context": "Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood."}, {"qas": [{"id": "6431f7de57b1c7a31500001b_005", "question": "What gene is mutated in Friedreich's ataxia?", "answers": []}], "context": "We now report a quantitative assay for frataxin proteoforms in whole blood from healthy controls and FRDA patients. "}, {"qas": [{"id": "6431f7de57b1c7a31500001b_006", "question": "What gene is mutated in Friedreich's ataxia?", "answers": []}], "context": "The mean levels of mature frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001) at 7.5 \u00b1 1.5 ng/mL and 2.1 \u00b1 1.2 ng/mL, respectively. "}, {"qas": [{"id": "6431f7de57b1c7a31500001b_007", "question": "What gene is mutated in Friedreich's ataxia?", "answers": []}], "context": "he mean levels of total frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001) at 34.2 \u00b1 4.3 ng/mL and 6.8 \u00b1 4.0 ng/mL, respectively. "}, {"qas": [{"id": "643f9eeb57b1c7a31500003c_001", "question": "What is the incidence of Duchenne Muscular Dystrophy?", "answers": []}], "context": "Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births."}, {"qas": [{"id": "643f9eeb57b1c7a31500003c_002", "question": "What is the incidence of Duchenne Muscular Dystrophy?", "answers": []}], "context": "The cumulative incidence of disease was 19.7 per 100,000 male live births and 1 in 5076 live born males were diagnosed with DMD."}, {"qas": [{"id": "6415c252690f196b51000011_001", "question": "Which cancer is the BCG vaccine used for?", "answers": []}], "context": "Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status."}, {"qas": [{"id": "6415c252690f196b51000011_002", "question": "Which cancer is the BCG vaccine used for?", "answers": []}], "context": "In the past decades, the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer, especially for intermediate and high-risk groups, is increasingly accepted by multiple guidelines. Currently, the front-line setting for the high-risk group is still intravesical BCG instillation."}, {"qas": [{"id": "63eeed0af36125a426000007_001", "question": "What disease can be treated with Teclistamab?", "answers": []}], "context": "Teclistamab in Relapsed or Refractory Multiple Myeloma."}, {"qas": [{"id": "63eeed0af36125a426000007_002", "question": "What disease can be treated with Teclistamab?", "answers": []}], "context": "In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma."}, {"qas": [{"id": "63eeed0af36125a426000007_003", "question": "What disease can be treated with Teclistamab?", "answers": []}], "context": "CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma."}, {"qas": [{"id": "63eeed0af36125a426000007_004", "question": "What disease can be treated with Teclistamab?", "answers": []}], "context": "Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma."}, {"qas": [{"id": "63eeed0af36125a426000007_005", "question": "What disease can be treated with Teclistamab?", "answers": []}], "context": "BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies."}, {"qas": [{"id": "63f03ea0f36125a426000020_001", "question": "SER-109 is developed for prevention of which disease?", "answers": []}], "context": "In ECOSPOR III, SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI. "}, {"qas": [{"id": "63f03ea0f36125a426000020_002", "question": "SER-109 is developed for prevention of which disease?", "answers": []}], "context": "SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection."}, {"qas": [{"id": "63f03ea0f36125a426000020_003", "question": "SER-109 is developed for prevention of which disease?", "answers": []}], "context": "SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection."}, {"qas": [{"id": "63f03ea0f36125a426000020_004", "question": "SER-109 is developed for prevention of which disease?", "answers": []}], "context": "We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2."}, {"qas": [{"id": "64179113690f196b5100002e_001", "question": "Where is the DMD gene located?", "answers": []}], "context": "The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus."}, {"qas": [{"id": "64179113690f196b5100002e_002", "question": "Where is the DMD gene located?", "answers": []}], "context": "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21."}, {"qas": [{"id": "64179113690f196b5100002e_003", "question": "Where is the DMD gene located?", "answers": []}], "context": "The disease is caused by deletion, duplication or point mutation of the dystrophin gene, located on the X chromosome (Xp21). "}, {"qas": [{"id": "6415c9e9690f196b51000018_001", "question": "Which form of breast cancer has Keytruda been FDA approved for?", "answers": []}], "context": "The combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC, as the FDA recently approved atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in combination with chemotherapy. "}], "title": "BioASQ8b"}], "version": "BioASQ8b"}